Nykode Therapeutics (Buy, TP: NOK4.00) - Transition on track
While the Q4 report contained no big surprises, Nykode Therapeutics said its transition into a “leaner, research- and technology-driven organisation” is on track. CFO Harald Gurvin said he believes it could reach the targeted cost base of cUSD20m per annum as soon as 2026. Following the strategic pivot, the company is focusing on: 1) asset generation; and 2) value creation through seeking early-stage partnerships. We reiterate our BUY and NOK4 target price.Vaccibody AS. Vaccibody AS is a Norway-based vaccine company. It is engaged in the development of vaccines that overcome the shortcomings of current vaccine technologies. The Company's vaccine platform increases the antibody and T-cell responses. The Company focuses on cancer vaccines, partnering the technology within infection and veterinary use. The Company develops of an immuntherapy against HPV-induced malignancies, such as precanceous lesions of cervical cancer. The major shareholders of the Company are BMI, Sarsia Seed and the investors.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.